产品
编 号：F546641
分子式：C24H31FO6
分子量：434.5
分子式：C24H31FO6
分子量：434.5
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 3385-03-3
产品详情
生物活性：
Flunisolide is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation.
体内研究：
Flunisolide (Intranasal administration, 0.3–10 μg/mouse, daily, from days 21-27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice.Flunisolide (Intranasal administration, 0.3–10 μg/mouse, daily, from days 21-27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue.Animal Model:Male Swiss Webster mice (instilled, intranasally, with crystalline silica, 10 mg/50 μL, particle size 0.5-10 μm)
Dosage:0.3-10 μg/mouse, daily, from days 21–27
Administration:Intranasal administration
Result:Reduced both granulomatous response, collagen deposition, concerning granuloma formation caused by silica particles.Reduced the number of F4/80 and α-SMA positive cells.
体外研究：
Flunisolide (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation.Flunisolide (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated frommild to moderate asthmatics), and induces sputum eosinophil apoptosis.Flunisolide (0.1-10 μM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells.Flunisolide (115 μM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent.
Flunisolide is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation.
体内研究：
Flunisolide (Intranasal administration, 0.3–10 μg/mouse, daily, from days 21-27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice.Flunisolide (Intranasal administration, 0.3–10 μg/mouse, daily, from days 21-27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue.Animal Model:Male Swiss Webster mice (instilled, intranasally, with crystalline silica, 10 mg/50 μL, particle size 0.5-10 μm)
Dosage:0.3-10 μg/mouse, daily, from days 21–27
Administration:Intranasal administration
Result:Reduced both granulomatous response, collagen deposition, concerning granuloma formation caused by silica particles.Reduced the number of F4/80 and α-SMA positive cells.
体外研究：
Flunisolide (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation.Flunisolide (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated frommild to moderate asthmatics), and induces sputum eosinophil apoptosis.Flunisolide (0.1-10 μM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells.Flunisolide (115 μM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备